Genital Herpes - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Genital Herpes - Pipeline Review, H1 2019’, provides an overview of the Genital Herpes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Genital Herpes

- The report reviews pipeline therapeutics for Genital Herpes by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Genital Herpes therapeutics and enlists all their major and minor projects

- The report assesses Genital Herpes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Genital Herpes

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Genital Herpes

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

Admedus Ltd

AiCuris GmbH & Co KG

Auritec Pharmaceuticals Inc

Biomere LLC

BlueWillow Biologics Inc

Immune Design Corp

ISR Immune System Regulation Holding ...

Abivax SA

Admedus Ltd

AiCuris GmbH & Co KG

Auritec Pharmaceuticals Inc

Biomere LLC

BlueWillow Biologics Inc

Immune Design Corp

ISR Immune System Regulation Holding AB

NanoViricides Inc

Profectus BioSciences Inc

Redbiotec AG

Sanofi Pasteur SA

Stabilitech Biopharma Ltd

Starpharma Holdings Ltd

Vaccibody AS

Vaxart Inc

Vir Biotechnology Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Genital Herpes – Overview

Genital Herpes – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Genital Herpes – Overview

Genital Herpes – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Genital Herpes – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Genital Herpes – Companies Involved in Therapeutics Development

Abivax SA

Admedus Ltd

AiCuris GmbH & Co KG

Auritec Pharmaceuticals Inc

Biomere LLC

BlueWillow Biologics Inc

Immune Design Corp

ISR Immune System Regulation Holding AB

NanoViricides Inc

Profectus BioSciences Inc

Redbiotec AG

Sanofi Pasteur SA

Stabilitech Biopharma Ltd

Starpharma Holdings Ltd

Vaccibody AS

Vaxart Inc

Vir Biotechnology Inc

Genital Herpes – Drug Profiles

ABX-196 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acyclovir SR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aspidasept – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

astodrimer – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-103 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes (virus like particle) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GV-2207 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus [type 1, 2] vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSV-529 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pritelivir – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Profavax HSV-1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Profavax HSV-2 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLV-20 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Genital Herpes – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Theravax HSV-1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Theravax HSV-2 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

triptorelin acetate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMTX-004 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Genital Herpes – Dormant Projects

Genital Herpes – Discontinued Products

Genital Herpes – Product Development Milestones

Featured News & Press Releases

May 04, 2017: Admedus Releases Results of HSV-2 Phase IIa Study

Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine

Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes

Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II Interim Data

Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging

Feb 03, 2016: Model helps decide drug dose for clinical testing

Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine

Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015

Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences

Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection

Oct 02, 2014: Admedus Announces Further Data From Herpes Simplex Vaccine Trial

Feb 03, 2014: Admedus Herpes Interim Phase I Results

Oct 17, 2013: ALLIED HERPES PHASE I TRIAL PROGRESS UPDATE

Jun 19, 2013: Allied Healthcare Receives Ethical Approval To Commence Phase I Clinical Trial Of HSV-2 Vaccine

Jan 29, 2013: AiCuris Surpasses 50% Enrollment Milestone In Phase II Trial For Herpes Drug Pritelivir

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Genital Herpes, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Tables

Number of Products under Development for Genital Herpes, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Genital Herpes – Pipeline by Abivax SA, H1 2019

Genital Herpes – Pipeline by Admedus Ltd, H1 2019

Genital Herpes – Pipeline by AiCuris GmbH & Co KG, H1 2019

Genital Herpes – Pipeline by Auritec Pharmaceuticals Inc, H1 2019

Genital Herpes – Pipeline by Biomere LLC, H1 2019

Genital Herpes – Pipeline by BlueWillow Biologics Inc, H1 2019

Genital Herpes – Pipeline by Immune Design Corp, H1 2019

Genital Herpes – Pipeline by ISR Immune System Regulation Holding AB, H1 2019

Genital Herpes – Pipeline by NanoViricides Inc, H1 2019

Genital Herpes – Pipeline by Profectus BioSciences Inc, H1 2019

Genital Herpes – Pipeline by Redbiotec AG, H1 2019

Genital Herpes – Pipeline by Sanofi Pasteur SA, H1 2019

Genital Herpes – Pipeline by Stabilitech Biopharma Ltd, H1 2019

Genital Herpes – Pipeline by Starpharma Holdings Ltd, H1 2019

Genital Herpes – Pipeline by Vaccibody AS, H1 2019

Genital Herpes – Pipeline by Vaxart Inc, H1 2019

Genital Herpes – Pipeline by Vir Biotechnology Inc, H1 2019

Genital Herpes – Dormant Projects, H1 2019

Genital Herpes – Dormant Projects, H1 2019 (Contd..1), H1 2019

Genital Herpes – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Genital Herpes, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Figures

Number of Products under Development for Genital Herpes, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports